Palmitoyl Tripeptide-1
A collagen-boosting cosmetic peptide that mimics the body's wound-healing signal to stimulate collagen and elastin production in the skin.
What is Palmitoyl Tripeptide-1?
Palmitoyl Tripeptide-1 is a lipopeptide consisting of palmitic acid linked to the tripeptide GHK (glycine-histidine-lysine). It is a synthetic fragment of collagen that functions as a matrikine — a messenger that signals fibroblasts to produce new collagen, elastin, and glycosaminoglycans. It is a key ingredient in Matrixyl 3000 (where it is combined with Palmitoyl Tetrapeptide-7) and is one of the most widely used anti-aging peptides in professional skincare.
What Palmitoyl Tripeptide-1 Is Investigated For
Palmitoyl Tripeptide-1 is a matrikine cosmeceutical peptide — a lipidated collagen fragment (GHK) used topically for collagen and elastin stimulation, wrinkle-depth reduction, and skin firmness, most commonly within the Matrixyl 3000 combination where it pairs with the anti-inflammatory Palmitoyl Tetrapeptide-7. The strongest evidence is in Matrixyl 3000 clinical studies, which show measurable wrinkle-depth reductions around 20–30% versus placebo at 8–16 weeks of twice-daily use; trials of the isolated peptide at matched concentrations are more limited. Matrikine signaling via GHK and TGF-beta-mediated fibroblast activation is a well-characterized mechanism, but most published efficacy data is supplier-associated (Sederma/Croda) and independent replication at clinically relevant concentrations is thin. It is an evidence-backed cosmetic active for incremental benefit when layered with retinoids and vitamin C — not a substitute for a retinoid and not remotely comparable to in-office collagen-stimulating procedures (fractional laser, poly-L-lactic acid, RF microneedling). Honest positioning: real cosmetic signaling, modest effect sizes, complementary to stronger actives.
History & Discovery
Palmitoyl Tripeptide-1 was developed by Sederma, the French active-ingredient subsidiary of Croda (and later in the L'Oréal orbit through licensing), as part of its late-1990s and early-2000s matrikine peptide line. The molecule is the GHK tripeptide (glycine-histidine-lysine, the same three-amino-acid fragment underlying the copper peptide GHK-Cu) conjugated to palmitic acid to create a lipidated, skin-penetrating cosmetic active. It is marketed commercially under trade names including Biopeptide CL and is sold as a cosmetic raw material for incorporation into finished formulations. The ingredient's most prominent commercial incarnation is in Matrixyl 3000, where Palmitoyl Tripeptide-1 is combined with Palmitoyl Tetrapeptide-7 (Pal-GQPR). Matrixyl 3000 followed the original Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) and extended the positioning from pure collagen stimulation to a combined collagen-stimulation-plus-anti-inflammation pitch. The clinical data supporting Palmitoyl Tripeptide-1's efficacy is largely generated by or associated with the supplier and licensees, with independent replication at clinically relevant concentrations more limited. Like all cosmetic peptides, its development pathway has been as a personal-care active rather than as a drug, so the evidence bar and claim language differ from pharmaceutical products.
How It Works
Palmitoyl Tripeptide-1 mimics a collagen fragment that your body produces when skin is damaged. When fibroblasts detect this signal, they ramp up production of new collagen, elastin, and hyaluronic acid — essentially tricking your skin into repairing itself from within.
The GHK sequence is a matrikine derived from type I collagen, fibronectin, and SPARC. When detected by dermal fibroblasts via TGF-beta receptor signaling, it activates the wound-healing cascade: upregulation of collagen types I, III, and IV synthesis, increased elastin production, and enhanced glycosaminoglycan (including hyaluronic acid) deposition. The palmitoyl modification (C16 fatty acid) dramatically improves penetration through the lipid-rich stratum corneum compared to the unmodified GHK tripeptide. In Matrixyl 3000, it is paired with Palmitoyl Tetrapeptide-7, which suppresses IL-6 and other pro-inflammatory cytokines, reducing the chronic low-grade inflammation (inflammaging) that accelerates collagen breakdown.
Evidence Snapshot
Human Clinical Evidence
Moderate. Clinical studies demonstrating significant wrinkle reduction and skin firmness improvement, primarily as part of the Matrixyl 3000 complex. Independent studies on the isolated peptide are more limited.
Animal / Preclinical
Moderate. In vitro fibroblast studies confirming collagen and ECM stimulation. The GHK sequence's matrikine signaling is well-established.
Mechanistic Rationale
Strong. Matrikine signaling via the GHK fragment and TGF-beta-mediated collagen synthesis are well-characterized pathways.
Research Gaps & Open Questions
What the current literature has not yet settled about Palmitoyl Tripeptide-1:
- 01Independent, non-industry-funded human clinical trials — most published efficacy data for Palmitoyl Tripeptide-1 and Matrixyl 3000 is supplier-associated, and independent replication at clinically relevant concentrations and durations is thin.
- 02Isolated Palmitoyl Tripeptide-1 efficacy — most clinical data is for the Matrixyl 3000 complex; whether Palmitoyl Tripeptide-1 alone produces the same benefit as the Pal-3/Pal-7 combination is not well characterized.
- 03Skin-penetration quantification in commercial formulations — delivery to viable epidermis and papillary dermis varies substantially by vehicle; real-world effective dose at the fibroblast is not well mapped across available products.
- 04Head-to-head comparison with established anti-aging actives — whether Palmitoyl Tripeptide-1 adds meaningful incremental benefit on top of a retinoid, or delivers comparable benefit on its own, is not rigorously established.
- 05Long-term (multi-year) use data — most trials run 8–16 weeks; whether chronic use over years meaningfully alters skin-aging trajectory differently from shorter windows has not been studied.
- 06Responder vs. non-responder characterization — response to matrikine peptides is variable and the biological basis (baseline collagen status, skin thickness, concurrent actives) is not well understood.
Forms & Administration
Topical application in serums and creams. Typically found in formulations at 100-500 ppm. Applied twice daily. Often formulated alongside Palmitoyl Tetrapeptide-7 (as Matrixyl 3000) or with other active ingredients like hyaluronic acid and niacinamide.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Finished cosmetic products typically include Palmitoyl Tripeptide-1 at 100–500 ppm (parts per million), which translates to roughly 0.01–0.05% of the formula — often combined with Palmitoyl Tetrapeptide-7 in Matrixyl 3000 formulations at similar low concentrations. Supplier guidance for Matrixyl 3000 is typically 2–4% of the finished product by weight of the raw material (the raw material itself is diluted). Higher nominal label percentages sometimes appear in marketing but, as with all topical peptides, vehicle formulation and skin penetration govern real-world delivered dose far more than bulk concentration above a certain threshold.
Frequency
Applied once or twice daily to clean skin. Published and supplier-referenced trial protocols generally use twice-daily application (AM and PM) for 8–16 weeks before measuring wrinkle-depth, firmness, and elasticity endpoints.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous indefinite use. Matrikine signaling is a chronic stimulus; there is no cycling rationale in the cosmetic peptide literature. Benefit recedes with discontinuation as collagen turnover replaces treated tissue.
Protocol Notes
The palmitoyl modification is the entire delivery strategy: palmitic acid conjugation improves partition into the lipid-rich stratum corneum, the outermost barrier of the epidermis. Without the C16 fatty acid, the bare GHK tripeptide (roughly 340 Da) is hydrophilic and penetrates poorly; with lipidation (roughly 578 Da, but amphipathic), penetration improves substantially — though even lipidated, only a modest fraction of applied peptide reaches viable epidermis and the papillary dermis where fibroblasts actually live. This delivery reality is the main reason effect sizes in cosmetic-peptide trials are measurable but modest. In practice, Palmitoyl Tripeptide-1 is almost never used alone — it is formulated alongside Palmitoyl Tetrapeptide-7 (for anti-inflammatory action), copper peptides, Argireline-family neuropeptides, and established actives (retinoids, vitamin C, niacinamide, hyaluronic acid). Retinoids and matrikines are typically regarded as complementary: retinoids via retinoic acid receptor activation and global epidermal turnover, matrikines via TGF-β-family signaling on fibroblasts. Strong acids and high-concentration vitamin C are best separated to a different time of day to avoid destabilizing the peptide in the vehicle. Injection or compounding for systemic use is not an established category for Palmitoyl Tripeptide-1 — these are cosmetic topical actives, not injectable peptides, and there is no clinical rationale or safety basis for injection. That distinguishes it from the unmodified GHK tripeptide, which is more commonly discussed in copper-complexed form (GHK-Cu) with some injectable use.
Palmitoyl Tripeptide-1 is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic product claims are limited to appearance-related language under FDA cosmetic rules.
Timeline of Effects
Onset
Surface-level smoothing and hydration effects from the cosmetic vehicle appear within days. Fibroblast-mediated collagen signaling requires weeks to produce measurable changes; published trials typically begin to report statistically significant wrinkle-depth or firmness improvement at 4–8 weeks of twice-daily application.
Peak Effect
Maximum measured effect in clinical trials is typically reported at 8–16 weeks of consistent twice-daily use, with reported wrinkle-depth reductions in the 20–30% range for Matrixyl 3000 formulations versus placebo at well-standardized imaging endpoints. Continued use is generally assumed to maintain the benefit rather than produce ongoing incremental gains beyond that window.
After Discontinuation
Benefits recede gradually over weeks to months as collagen turnover replaces treated tissue and the matrikine signal is withdrawn. No rebound or withdrawal pattern is described — skin returns toward its pre-treatment aging trajectory, not to a worse state than before.
Common Questions
Who Palmitoyl Tripeptide-1 Is NOT For
- •Broken, irritated, or actively inflamed skin — wait for barrier recovery before applying cosmetic peptide serums.
- •Known hypersensitivity to Palmitoyl Tripeptide-1 or to other components of the cosmetic vehicle (preservatives, fragrances, emulsifiers). Contact dermatitis is uncommon but reported with cosmetic peptide products.
- •Pregnancy and breastfeeding — topical cosmetic use on intact skin is generally considered low-risk, but dedicated pregnancy safety data is absent and a conservative default is to minimize optional active-peptide cosmetics during this window.
- •Pediatric use — no indication and no reason for children or adolescents to use anti-wrinkle peptide products.
- •History of severe reactions to topical peptide or lipopeptide formulations.
- •Do not inject cosmetic Palmitoyl Tripeptide-1 preparations — these are not sterile injectable products and there is no clinical rationale or safety basis for injection.
Drug & Supplement Interactions
Documented pharmacological drug interactions for topical Palmitoyl Tripeptide-1 are minimal. Systemic absorption from typical topical use is low, and the lipidated peptide is not expected to reach clinically relevant plasma levels or interact meaningfully with oral or injected medications. The relevant interaction space is topical layering with other cosmetic actives and dermatologic drugs. Compatibility is broad. Palmitoyl Tripeptide-1 layers well with hyaluronic acid, ceramides, niacinamide, and other peptides. Retinoids (retinol, tretinoin) are commonly paired with Palmitoyl Tripeptide-1 and the combination is regarded as complementary rather than antagonistic. High-concentration L-ascorbic acid (vitamin C) is acidic enough that simultaneous same-layer application can destabilize peptide actives, so vitamin C is typically used at a different time of day. Strong AHA or BHA exfoliation on the same evening as a matrikine peptide application may reduce peptide integrity at the surface and increase irritation, so spacing is a sensible default. Palmitoyl Tripeptide-1 does not interact with anticoagulants, hormonal therapies, or systemic medications at the level of topical cosmetic exposure. Patients on prescription topical dermatologic therapies (tretinoin, tazarotene, hydroquinone, clindamycin-benzoyl peroxide) should coordinate routines with their dermatologist, primarily for irritation management rather than true drug interaction.
Safety Profile
Common Side Effects
Cautions
- • Topical use only — not for injection
- • Effects require consistent application over 8-12 weeks
- • Quality and concentration vary between products
What We Don't Know
Long-term safety profile is favorable based on extensive use in cosmetic formulations worldwide.
Legal Status
United States
Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Permitted for over-the-counter sale in finished cosmetic formulations without prescription. Palmitoyl Tripeptide-1 is listed in the Personal Care Products Council's ingredient dictionary (as Palmitoyl Tripeptide-1 and under its oligopeptide nomenclature) and is in widespread commercial use. Not FDA-approved as a drug for wrinkles or any medical indication.
International
Permitted as a cosmetic ingredient across the EU, UK, Canada, Australia, Japan, China, and most major markets. CIR (Cosmetic Ingredient Review) and analogous bodies have assessed palmitoyl peptide cosmetic ingredients as safe at typical formulation levels. No jurisdictions treat it as a prescription-only or regulated substance.
Sports & Competition
Not listed on the WADA Prohibited List and not a realistic doping concern. Topical cosmetic peptides operate at the skin surface with negligible systemic exposure relevant to performance enhancement.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Palmitoyl Tripeptide-1 produces results comparable to professional collagen-stimulating treatments.
Reality
It is a legitimate cosmetic active that modestly upregulates collagen-related gene expression in the skin it actually reaches. Treatments that produce dramatic collagen remodeling — fractional laser, RF microneedling, injectable biostimulators like poly-L-lactic acid — operate at a different depth and scale. Palmitoyl Tripeptide-1 complements those treatments; it does not substitute for them.
Myth
Because it shares the GHK sequence with GHK-Cu, Palmitoyl Tripeptide-1 is interchangeable with copper peptides.
Reality
Both start from GHK, but the pharmacology diverges at the modification. GHK-Cu's activity depends significantly on copper binding and copper-mediated effects on enzymes and redox chemistry. Palmitoyl Tripeptide-1 relies on the palmitoyl group for skin penetration and operates primarily as a matrikine signal without the copper-dependent biology. They are related but not interchangeable.
Myth
Higher-concentration Palmitoyl Tripeptide-1 products give proportionally better results.
Reality
Above the typical 100–500 ppm range in finished products, additional concentration increases label appeal more than clinical effect. The bottleneck is the stratum corneum, not the bulk peptide in the serum. Formulation (vehicle, pH, encapsulation, lipid delivery) affects delivered dose more than nominal peptide percentage.
Myth
Palmitoyl Tripeptide-1 replaces a retinoid.
Reality
Retinoids have decades of dermatologic evidence for photoaging, texture, and acne — a different order of evidence than cosmetic matrikine peptides. Palmitoyl Tripeptide-1 is better thought of as complementary: it layers well with retinoids and may add marginal benefit, but it is not a substitute for a retinoid in someone whose skin tolerates one.
Myth
Topical cosmetic peptides can be injected for stronger effects.
Reality
Cosmetic Palmitoyl Tripeptide-1 preparations are not sterile injectable products, are not formulated for parenteral use, and have no clinical rationale for injection. Injecting a cosmetic-grade preparation introduces risks of infection, contamination, and adverse reaction to excipients not designed for injection — with no established efficacy benefit over topical use.
Published Research
2 studiesAn anti-aging skin care system containing alpha hydroxy acids and vitamins improves the biomechanical parameters of facial skin
Skin anti-aging strategies
Review of anti-aging mechanisms including matrikine peptide signaling, placing Palmitoyl Tripeptide-1 in context with retinoids, antioxidants, and growth factors.
Quick Facts
- Class
- Signal Peptide (Cosmetic)
- Tier
- C
- Evidence
- Moderate
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 2PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.